Breast tumor contamination of PBSC harvests: Tumor depletion by positive selection of CD34+ cells

J. Burgess, B. Mills, M. Griffith, V. Mansour, C. H. Weaver, Lee Schwartzberg, E. L. Snyder, D. S. Krause, S. Yanovich, M. Prilutskaya, T. Umiel, T. J. Moss

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Positive selection of CD34+ cells may reduce or eliminate tumor cells contaminating PBSC harvests of breast cancer (BrCa) patients. However, to assess tumor purging accurately methods may be needed that are of higher sensitivity than standard immunocytochemistry (ICC) assays. Methods: BrCa-cell depletion, resulting from CD34+ cell selection, was evaluated using a novel, highly sensitive assay based upon immunomagnetic enrichment with ICC detection in 36 BrCa patients undergoing high-dose chemotherapy with autologous PBSC support. Results: The prevalence of BrCa-cell contamination was significantly lower (P = 0.0078) in selected CD34+ cell fractions (17/35, 49%) from apheresis collections compared with CD34- cell fractions (25/35, 71%). In 8/34 (24%) patients, BrCa cells were detected in CD34- cell fractions, but not in paired CD34+ cell fractions. Significantly lower total numbers (P < 0.0005) of BrCa cells were enumerable in CD34+ cell fractions compared with corresponding apheresis harvests. The median total BrCa-cell content of selected CD34+ cell fractions with measurable contamination was 22 BrCa cells (range, 6-73 BrCa cells), compared with 3297 BrCa cells (range, 10-98 400 BrCa cells) in apheresis harvests. The median log depletion of BrCa cells achieved by positive CD34+ cell selection in specimens with detectable contamination both before and after selection was 2.2 (range, 1.7-4.0). Total pre-selection BrCa cell number was significantly predictive (P = 0.004) of residual detectable post-selection contamination. Discussion: Positive CD34+ cell selection is an effective tumor purging strategy. The prevalence of PBSC contamination in BrCa patients is substantially higher than formerly appreciated.

Original languageEnglish (US)
Pages (from-to)285-294
Number of pages10
JournalCytotherapy
Volume3
Issue number4
DOIs
StatePublished - Jan 1 2001

Fingerprint

Breast Neoplasms
Neoplasms
Blood Component Removal
Immunohistochemistry
Cell Count

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Transplantation
  • Cancer Research

Cite this

Breast tumor contamination of PBSC harvests : Tumor depletion by positive selection of CD34+ cells. / Burgess, J.; Mills, B.; Griffith, M.; Mansour, V.; Weaver, C. H.; Schwartzberg, Lee; Snyder, E. L.; Krause, D. S.; Yanovich, S.; Prilutskaya, M.; Umiel, T.; Moss, T. J.

In: Cytotherapy, Vol. 3, No. 4, 01.01.2001, p. 285-294.

Research output: Contribution to journalArticle

Burgess, J, Mills, B, Griffith, M, Mansour, V, Weaver, CH, Schwartzberg, L, Snyder, EL, Krause, DS, Yanovich, S, Prilutskaya, M, Umiel, T & Moss, TJ 2001, 'Breast tumor contamination of PBSC harvests: Tumor depletion by positive selection of CD34+ cells', Cytotherapy, vol. 3, no. 4, pp. 285-294. https://doi.org/10.1080/146532401317070925
Burgess, J. ; Mills, B. ; Griffith, M. ; Mansour, V. ; Weaver, C. H. ; Schwartzberg, Lee ; Snyder, E. L. ; Krause, D. S. ; Yanovich, S. ; Prilutskaya, M. ; Umiel, T. ; Moss, T. J. / Breast tumor contamination of PBSC harvests : Tumor depletion by positive selection of CD34+ cells. In: Cytotherapy. 2001 ; Vol. 3, No. 4. pp. 285-294.
@article{5e1b8f87782943398ec80135ae477e1f,
title = "Breast tumor contamination of PBSC harvests: Tumor depletion by positive selection of CD34+ cells",
abstract = "Background: Positive selection of CD34+ cells may reduce or eliminate tumor cells contaminating PBSC harvests of breast cancer (BrCa) patients. However, to assess tumor purging accurately methods may be needed that are of higher sensitivity than standard immunocytochemistry (ICC) assays. Methods: BrCa-cell depletion, resulting from CD34+ cell selection, was evaluated using a novel, highly sensitive assay based upon immunomagnetic enrichment with ICC detection in 36 BrCa patients undergoing high-dose chemotherapy with autologous PBSC support. Results: The prevalence of BrCa-cell contamination was significantly lower (P = 0.0078) in selected CD34+ cell fractions (17/35, 49{\%}) from apheresis collections compared with CD34- cell fractions (25/35, 71{\%}). In 8/34 (24{\%}) patients, BrCa cells were detected in CD34- cell fractions, but not in paired CD34+ cell fractions. Significantly lower total numbers (P < 0.0005) of BrCa cells were enumerable in CD34+ cell fractions compared with corresponding apheresis harvests. The median total BrCa-cell content of selected CD34+ cell fractions with measurable contamination was 22 BrCa cells (range, 6-73 BrCa cells), compared with 3297 BrCa cells (range, 10-98 400 BrCa cells) in apheresis harvests. The median log depletion of BrCa cells achieved by positive CD34+ cell selection in specimens with detectable contamination both before and after selection was 2.2 (range, 1.7-4.0). Total pre-selection BrCa cell number was significantly predictive (P = 0.004) of residual detectable post-selection contamination. Discussion: Positive CD34+ cell selection is an effective tumor purging strategy. The prevalence of PBSC contamination in BrCa patients is substantially higher than formerly appreciated.",
author = "J. Burgess and B. Mills and M. Griffith and V. Mansour and Weaver, {C. H.} and Lee Schwartzberg and Snyder, {E. L.} and Krause, {D. S.} and S. Yanovich and M. Prilutskaya and T. Umiel and Moss, {T. J.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1080/146532401317070925",
language = "English (US)",
volume = "3",
pages = "285--294",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Breast tumor contamination of PBSC harvests

T2 - Tumor depletion by positive selection of CD34+ cells

AU - Burgess, J.

AU - Mills, B.

AU - Griffith, M.

AU - Mansour, V.

AU - Weaver, C. H.

AU - Schwartzberg, Lee

AU - Snyder, E. L.

AU - Krause, D. S.

AU - Yanovich, S.

AU - Prilutskaya, M.

AU - Umiel, T.

AU - Moss, T. J.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Background: Positive selection of CD34+ cells may reduce or eliminate tumor cells contaminating PBSC harvests of breast cancer (BrCa) patients. However, to assess tumor purging accurately methods may be needed that are of higher sensitivity than standard immunocytochemistry (ICC) assays. Methods: BrCa-cell depletion, resulting from CD34+ cell selection, was evaluated using a novel, highly sensitive assay based upon immunomagnetic enrichment with ICC detection in 36 BrCa patients undergoing high-dose chemotherapy with autologous PBSC support. Results: The prevalence of BrCa-cell contamination was significantly lower (P = 0.0078) in selected CD34+ cell fractions (17/35, 49%) from apheresis collections compared with CD34- cell fractions (25/35, 71%). In 8/34 (24%) patients, BrCa cells were detected in CD34- cell fractions, but not in paired CD34+ cell fractions. Significantly lower total numbers (P < 0.0005) of BrCa cells were enumerable in CD34+ cell fractions compared with corresponding apheresis harvests. The median total BrCa-cell content of selected CD34+ cell fractions with measurable contamination was 22 BrCa cells (range, 6-73 BrCa cells), compared with 3297 BrCa cells (range, 10-98 400 BrCa cells) in apheresis harvests. The median log depletion of BrCa cells achieved by positive CD34+ cell selection in specimens with detectable contamination both before and after selection was 2.2 (range, 1.7-4.0). Total pre-selection BrCa cell number was significantly predictive (P = 0.004) of residual detectable post-selection contamination. Discussion: Positive CD34+ cell selection is an effective tumor purging strategy. The prevalence of PBSC contamination in BrCa patients is substantially higher than formerly appreciated.

AB - Background: Positive selection of CD34+ cells may reduce or eliminate tumor cells contaminating PBSC harvests of breast cancer (BrCa) patients. However, to assess tumor purging accurately methods may be needed that are of higher sensitivity than standard immunocytochemistry (ICC) assays. Methods: BrCa-cell depletion, resulting from CD34+ cell selection, was evaluated using a novel, highly sensitive assay based upon immunomagnetic enrichment with ICC detection in 36 BrCa patients undergoing high-dose chemotherapy with autologous PBSC support. Results: The prevalence of BrCa-cell contamination was significantly lower (P = 0.0078) in selected CD34+ cell fractions (17/35, 49%) from apheresis collections compared with CD34- cell fractions (25/35, 71%). In 8/34 (24%) patients, BrCa cells were detected in CD34- cell fractions, but not in paired CD34+ cell fractions. Significantly lower total numbers (P < 0.0005) of BrCa cells were enumerable in CD34+ cell fractions compared with corresponding apheresis harvests. The median total BrCa-cell content of selected CD34+ cell fractions with measurable contamination was 22 BrCa cells (range, 6-73 BrCa cells), compared with 3297 BrCa cells (range, 10-98 400 BrCa cells) in apheresis harvests. The median log depletion of BrCa cells achieved by positive CD34+ cell selection in specimens with detectable contamination both before and after selection was 2.2 (range, 1.7-4.0). Total pre-selection BrCa cell number was significantly predictive (P = 0.004) of residual detectable post-selection contamination. Discussion: Positive CD34+ cell selection is an effective tumor purging strategy. The prevalence of PBSC contamination in BrCa patients is substantially higher than formerly appreciated.

UR - http://www.scopus.com/inward/record.url?scp=18444370254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444370254&partnerID=8YFLogxK

U2 - 10.1080/146532401317070925

DO - 10.1080/146532401317070925

M3 - Article

C2 - 12171717

AN - SCOPUS:18444370254

VL - 3

SP - 285

EP - 294

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 4

ER -